Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited
- P/E ratio
- 89.35
Your view on TLX.AX
Overview
What the company does, where it operates, and who runs it.
About Telix Pharmaceuticals Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Christian Behrenbruch
- Headquarters
- 55 Flemington Road, North Melbourne, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Christian Behrenbruch
- Headquarters
- 55 Flemington Road, North Melbourne, VIC, AU
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products.
These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates.
TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases.
In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer.
For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer.
Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations.
This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Telix Pharmaceuticals Limited. Starting points for Telix Pharmaceuticals Limited: P/E 89.4, EPS AUD 0.10, beta 0.63 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Telix Pharmaceuticals Limited. Telix Pharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Telix Pharmaceuticals Limited. Trailing twelve-month EPS for Telix Pharmaceuticals Limited stands at AUD 0.10. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterJun 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$0.12 | −$0.07 | $0.12 | $0.07 |
| Lowest estimate | −$0.14 | −$0.08 | −$0.07 | −$0.49 |
| Highest estimate | −$0.09 | −$0.06 | $0.37 | $0.57 |
| Number of analysts | 1 | 1 | 11 | 7 |
| A year ago | $0.181 | −$0.011 | −$0.021 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterJun 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $29.52M | $127.62M | $1.46B | $1.88B |
| Lowest estimate | $24.80M | $107.21M | $1.43B | $1.76B |
| Highest estimate | $32.80M | $141.82M | $1.51B | $2.12B |
| Number of analysts | 3 | 1 | 14 | 8 |
| A year ago | $594.24M | $355.14M | $816.72M | — |
| Growth vs a year ago | −95.0% | −64.1% | +78.4% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Telix Pharmaceuticals Limited. Telix Pharmaceuticals Limited has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| CU6.AXClarity Pharmaceuticals Ltd | Healthcare | Medical - Specialties | — | ||
| RAD.AXRadiopharm Theranostics Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PHMMFPharma Mar, S.A. | Healthcare | OTC | $1.5B | ||
| PHRM.CNPharmaTher Holdings Ltd. | Healthcare | CNQ | $9.1M | ||
| PHRRFPharmaTher Holdings Ltd. | Healthcare | OTC | $5.3M | ||
| PHVSPharvaris N.V. | Healthcare | NASDAQ | $2.2B | ||
| PHYOFIXICO plc | Healthcare | OTC | $6.5M | ||
| PKTXProtoKinetix, Incorporated | Healthcare | OTC | $2.7M | ||
| PLRXPliant Therapeutics, Inc. | Healthcare | NASDAQ | $36.9M | ||
| PLRZPolyrizon Ltd. | Healthcare | NASDAQ | $10.4M | ||
| PLURPluri Inc. | Healthcare | NASDAQ | $10.1M | ||
| PLXProtalix BioTherapeutics, Inc. | Healthcare | AMEX | $244.5M | ||
| PLYXPolaryx Therapeutics, Inc. Common Stock | Healthcare | NASDAQ | $66.3M | ||
| PMCBPharmaCyte Biotech, Inc. | Healthcare | NASDAQ | $2.2M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VXUSVanguard Total International Stock ETF | $163.2B in assets | 0.01% | |
| VEAVanguard FTSE Developed Markets ETF | $231.6B in assets | 0.01% | |
| IEFAiShares Core MSCI EAFE ETF | $188.8B in assets | 0.01% | |
| SCZiShares MSCI EAFE Small-Cap ETF | $12.6B in assets | 0.07% | |
| ISCFiShares International Small-Cap Equity Factor ETF | $717M in assets | 0.07% | |
| IPACiShares Core MSCI Pacific ETF | $2.6B in assets | 0.03% | |
| VPLVanguard FTSE Pacific ETF | $9.0B in assets | 0.02% | |
| DFISDimensional - International Small Cap ETF | $5.8B in assets | 0.02% | |
Largest holders first, then the funds most concentrated in TLX.AX.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Telix Pharmaceuticals Limited. Coverage tracks Telix Pharmaceuticals Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Telix Pharmaceuticals Limited.